Spero Therapeutics (SPRO) Competitor Comparison
We are evaluating the key criteria listed to compare Spero Therapeutics (SPRO) against its competitors in the Biotechnology industry.
Market Capitalization
269 / 368Gross Profits
0 / 278Total Revenue
102 / 300EBITDA
31 / 337Free Cashflow
26 / 352Quick Ratio
231 / 357Earnings per Share
31 / 359Dividend yield
0 / 6Total Cash
221 / 358Performance 3 years
308 / 368Performance 5 years
272 / 368Performance 10 years
249 / 368Linearity 3 years
311 / 368Linearity 5 years
185 / 368Linearity 10 years
148 / 368Total Rank
266 / 368Dividend Rank
275 / 368Valuation Rank
99 / 368Piotroski Rank
145 / 368Muliplier Rank
50 / 368Market Capitalization - SPRO ranking 269 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.